T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Breast cancer research, 11.2009, Nr. 2, Art. R15, doi:10.1186/bcr2234
- Classification
-
Medizin, Gesundheit
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2009
- Creator
-
Rody, Achim
Holtrich, Uwe
Pusztai, Laos
Kolberg-Liedtke, Cornelia
Gätje, Regine
Ruckhäberle, Eugen
Solbach, Christine
Hanker, Lars
Ahr, André
Metzler, Dirk
Engels, Knut
Karn, Thomas
Kaufmann, Manfred
- URN
-
urn:nbn:de:hebis:30-64147
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rody, Achim
- Holtrich, Uwe
- Pusztai, Laos
- Kolberg-Liedtke, Cornelia
- Gätje, Regine
- Ruckhäberle, Eugen
- Solbach, Christine
- Hanker, Lars
- Ahr, André
- Metzler, Dirk
- Engels, Knut
- Karn, Thomas
- Kaufmann, Manfred
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2009
Other Objects (12)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer